-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China News Service, Beijing, April 22 (Reporter Sun Zifa) The world-renowned academic journal "Nature" recently published an immunological study on "Why the new crown vaccine developed for the original strain is still effective against Omicron" The paper shows that the third dose of the mRNA vaccine developed for the original new coronavirus (SARS-CoV-2) can enhance the ability of the immune system to produce broad-spectrum neutralizing antibodies, including the ability to neutralize Omi, compared with only two doses.
The research findings help explain why mRNA vaccines based on the original new coronavirus strain, as boosters, are still effective against newly created variants, the paper said
The co-corresponding author of the paper, Michel Nussenzweig of the Rockefeller University in the United States, and his colleagues and scientific colleagues cooperated with 42 people who had received three mRNA vaccines (8 vaccinated with Modena, 34 vaccinated with Pfizer- BioNTech) blood samples were analyzed, which were collected after the first, second and third doses, while none of the study participants had been infected with the new coronavirus
They observed that the blood samples after the third injection had an increased range of memory B cells compared to the blood samples after the second injection, and memory B cells can quickly respond to the new coronavirus and produce antibodies
The authors noted that the increased potency of the antibody after the third dose is because the antibodies produced by the emerging memory B cells can target more of the receptor-binding domain (the part of the virus that facilitates entry into host cells)